DEFR14A: Viking Therapeutics Seeks Stockholder Approval for CBIZ CPAs P.C. Appointment at 2025 Annual Meeting

Viking Therapeutics files an amendment to its proxy statement to reflect the appointment of CBIZ CPAs P.C. as the new independent registered public accounting firm for the fiscal year ending December 31, 2025, following Marcum LLP's resignation.

Summary

• Viking Therapeutics is holding its Annual Meeting of Stockholders virtually on May 20, 2025.
• The primary purpose of the meeting is to elect Class I directors, ratify the selection of CBIZ CPAs P.C. as the independent registered public accounting firm, and approve, on an advisory basis, the compensation of named executive officers.
• This amendment to the proxy statement is solely to reflect the change in the independent registered public accounting firm from Marcum LLP to CBIZ CPAs P.C. due to CBIZ's acquisition of Marcum's attest business.
• Stockholders of record as of March 31, 2025, are eligible to vote.
• The Board recommends voting for the election of the director nominees, for the ratification of CBIZ CPAs P.C., and for the approval of the executive compensation.
• The company's executive compensation program is designed to attract, retain, and motivate key talent, aligning their interests with those of stockholders.
• The company's executive compensation program is designed to reward achievement of the specific strategic goals that we believe will advance our business strategy and create long-term value for our stockholders.

Sentiment

Score: 7

Explanation: The document is a routine proxy statement amendment, indicating a neutral to slightly positive sentiment as the company is fulfilling its corporate governance obligations.

Positives

• The company is taking steps to ensure good corporate governance by seeking stockholder ratification of the appointment of the independent auditor.
• The company's executive compensation program is designed to align executive interests with stockholder returns and support the achievement of key business objectives.
• The company's executive compensation program is designed to reward achievement of the specific strategic goals that we believe will advance our business strategy and create long-term value for our stockholders.

Future Outlook

The company is focused on electing directors, ratifying the selection of CBIZ CPAs P.C., and approving executive compensation at the upcoming Annual Meeting.

Industry Context

The change in auditor reflects the consolidation occurring within the accounting industry, as CBIZ acquired Marcum's attest business.

Stakeholder Impact

• Stockholders are asked to vote on key proposals, including the election of directors and the ratification of the independent auditor.
• The outcome of the votes will influence the company's governance and financial oversight.

Next Steps

• Stockholders to vote on the proposals outlined in the proxy statement.
• The company to hold the Annual Meeting of Stockholders on May 20, 2025.
• The company to file a Form 8-K to disclose the voting results of the Annual Meeting.

Key Dates

Keywords

Viking Therapeutics, Annual Meeting, Proxy Statement, CBIZ CPAs P.C., Marcum LLP, Independent Auditor, Executive Compensation, Board of Directors, Stockholders, Corporate Governance